

RUBRA MEDICAMENTS LIMITED
 Unaudited Financial results for the Quarter and Nine Months Ended on December 31, 2014

Part I							(Rupees in Lacs)
Statement of Standalone Unaudited Results for the Quarter and Nine Months Ended 31/12/2014							
Sr. No	Particulars	For the Quarter Ended			For the Nine Months Ended		For the Year Ended
		31-12-14	30-09-14	31-12-13	31-12-14	31-12-13	31-03-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Net Sales/Income from Operations (Net of Excise Duty)	0.00	0.00	0.00	0.00	0.00	0.00
	Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (Net)	0.00	0.00	0.00	0.00	0.00	0.00
2	Expenses						
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
b	Cost of Goods Traded	0.00	0.00	0.00	0.00	0.00	0.00
c	Employee Cost	0.00	0.00	0.00	0.00	0.00	0.00
d	Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
e	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
f	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00	0.00	0.00
g	Other Expenses	1.61	1.42	1.62	5.54	4.27	5.86
	Total Expenses	1.61	1.42	1.62	5.54	4.27	5.86
3	Profit / (Loss) from Ordinary activities before other income, finance costs and exceptional items (1-2)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
6	Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
8	Exceptional Items						
a)	Depletion of Assets	0.00	0.00	0.00	0.00	0.00	0.00
b)	Write Offs	0.00	0.00	0.00	0.00	0.00	0.00
	Sub Total	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary activities before tax (7+8)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit / (Loss) from Ordinary activities after tax (9+10)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)	-1.61	-1.42	-1.62	-5.54	-4.27	-5.86
17	Paid-up equity share capital (Face value of the Share is Re.10/- each)	54,683,000	54,683,000	54,683,000	54,683,000	54,683,000	54,683,000
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year						
19.i	Earnings Per Share (EPS) (before Extraordinary items) (not to be annualized)						
a)	Basic	0.00	0.00	0.00	0.00	0.00	0.00
b)	Diluted	0.00	0.00	0.00	0.00	0.00	0.00
19.ii	Earnings Per Share (EPS) (after Extraordinary items) (not to be annualized)						
a)	Basic	0.00	0.00	0.00	0.00	0.00	0.00
b)	Diluted	0.00	0.00	0.00	0.00	0.00	0.00

PART II

Select information for the quarter ended on December 31, 2014

	Particulars	For the Quarter Ended			For the Nine Months Ended		For the Year Ended
		31-12-14	30-09-14	31-12-13	31-12-14	31-12-13	31-03-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	5,465,300	5,465,300	5,465,300	5,465,300	5,465,300	5,465,300
	- Percentage of shareholding	99.95	99.95	99.95	99.95	99.95	99.95
2	Promoters and promoter group Shareholding **						
a)	Pledged/Encumbered						
	Number of shares	0	0	0	0	0	0
b)	Non-encumbered						
	Number of Shares	3000	3000	3000	3000	3000	3000
	Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	Percentage of shares (as a % of the total share capital of the company)	0.05	0.05	0.05	0.05	0.05	0.05

Notes:

1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held on February 12, 2015.
2	The Company has no segments.
3	The result is provisional and unaudited and subject to change, regrouping and restatement.
4	NIL Complaints were received during the quarter and NIL complaints were pending to be resolved at the end of the Quarter.

Date: February 12, 2015
 Place: Hyderabad

For Rubra Medicaments Limited

